NOV.DE vs. 4AB.DE
Compare and contrast key facts about Novo Nordisk A/S (NOV.DE) and AbbVie Inc (4AB.DE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NOV.DE or 4AB.DE.
Key characteristics
NOV.DE | 4AB.DE | |
---|---|---|
YTD Return | 37.28% | 28.43% |
1Y Return | 49.18% | 26.99% |
3Y Return (Ann) | 53.42% | 28.92% |
5Y Return (Ann) | 54.72% | 27.31% |
10Y Return (Ann) | 44.07% | 19.02% |
Sharpe Ratio | 1.57 | 1.33 |
Daily Std Dev | 31.58% | 19.53% |
Max Drawdown | -87.90% | -36.94% |
Current Drawdown | -11.70% | -3.03% |
Fundamentals
NOV.DE | 4AB.DE | |
---|---|---|
Market Cap | €528.87B | €311.06B |
EPS | €2.69 | €2.70 |
PE Ratio | 44.11 | 64.76 |
PEG Ratio | 2.03 | 0.48 |
Total Revenue (TTM) | €93.49B | €55.00B |
Gross Profit (TTM) | €79.25B | €34.52B |
EBITDA (TTM) | €48.38B | €17.22B |
Correlation
The correlation between NOV.DE and 4AB.DE is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NOV.DE vs. 4AB.DE - Performance Comparison
In the year-to-date period, NOV.DE achieves a 37.28% return, which is significantly higher than 4AB.DE's 28.43% return. Over the past 10 years, NOV.DE has outperformed 4AB.DE with an annualized return of 44.07%, while 4AB.DE has yielded a comparatively lower 19.02% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NOV.DE vs. 4AB.DE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NOV.DE) and AbbVie Inc (4AB.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NOV.DE vs. 4AB.DE - Dividend Comparison
NOV.DE's dividend yield for the trailing twelve months is around 1.12%, less than 4AB.DE's 3.27% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk A/S | 1.12% | 1.01% | 1.18% | 1.27% | 1.99% | 2.09% | 5.96% | 2.28% | 3.69% | 1.25% | 1.69% | 1.82% |
AbbVie Inc | 3.27% | 3.87% | 3.53% | 3.67% | 4.88% | 4.31% | 3.54% | 2.73% | 3.26% | 0.00% | 0.00% | 0.00% |
Drawdowns
NOV.DE vs. 4AB.DE - Drawdown Comparison
The maximum NOV.DE drawdown since its inception was -87.90%, which is greater than 4AB.DE's maximum drawdown of -36.94%. Use the drawdown chart below to compare losses from any high point for NOV.DE and 4AB.DE. For additional features, visit the drawdowns tool.
Volatility
NOV.DE vs. 4AB.DE - Volatility Comparison
Novo Nordisk A/S (NOV.DE) has a higher volatility of 6.66% compared to AbbVie Inc (4AB.DE) at 4.14%. This indicates that NOV.DE's price experiences larger fluctuations and is considered to be riskier than 4AB.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NOV.DE vs. 4AB.DE - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and AbbVie Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities